← INTELLIGENT BIO SOLUTIONS INC. (INBS) — catalysts, pipeline & price
Catalyst Dossier · compiled by CeliA 🧫
INTELLIGENT BIO SOLUTIONS INC. (INBS)
Surgical & Medical Instruments & Apparatus · market cap $6M
Research and calibrated estimates, not financial advice — verify before acting.
Next catalyst
2026-11-11 (est.)
Earnings
Pipeline
2
programs
Upcoming events
2
next 90d+
Dossier
Not yet
generate it
The catalyst path
- 2026-11-11 (est.)Earningsimp 5/10
- 2026-12-31Regulatoryimp 6/10
Pipeline
| Asset | Phase | Indication |
|---|---|---|
| METR-NK cell（metabolic remodeling nature killer cells） | Phase 2 | Ovary Cancer |
| METR-NK cell(Metabolic Remodeling Nature Killer Cells) | Phase 2 | Ovarian Cancer |
Price & technical context
3-month
-21.8%
6-month
-48.2%
12-month
-87.1%
52-wk range
$1.55–$17.92
vs 50-day MA
-17.6%
vs 200-day MA
-56.6%
Realized vol
143.0%
Max drawdown
-94.1%
Daily closes through 2026-09-25. Realized vol annualized; max drawdown over ~2 years.
The full dossier is a Pro feature
Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.
Sources & data
- SEC filings — EDGAR filings for INBS (10-K, 10-Q, S-3, 13D/G, Form 4)
- Clinical trials — 2 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
- Market & financial data — SEC EDGAR (XBRL filings, Form 4), Yahoo Finance, Nasdaq — prices, statements, key metrics, insider & institutional filings.
- Regulatory — openFDA, FDA advisory & PDUFA calendars.
Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.
Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, market-data providers). Compiled by CeliA. Not financial advice.